title: Intraocular Lymphoma: Descriptive Data of 26 Patients Including Clinico-pathologic Features, Vitreous Findings, and Treatment Outcomes.
abstract: OBJECTIVE
  To describe clinical manifestations, diagnostic approaches, therapy, and outcomes of biopsy-proven intraocular lymphoma.
  
  
  METHODS
  Review of tertiary referral center records between 2005 and 2015.
  
  
  RESULTS
  A total of 51 eyes of 26 patients were included; mean age of onset was 60.42 years. Common ocular complaints included floaters (42%) and blurred vision (35%); 62% of patients had ocular and central nervous system involvement; 11% had systemic lymphoma; and 27% had only ocular involvement. Vitreous analysis was positive for malignant cells in 77% of patients on initial biopsy, and in 100% of patients on repeat biopsy. In total, 20/26 patients received systemic and topical treatment before IOL diagnosis was made; 25 patients received intravitreal methotrexate and/or rituximab; one patient received intracameral rituximab. All patients achieved remission by their final visit.
  
  
  CONCLUSIONS
  Intraocular lymphoma often masquerades as intraocular inflammation, resulting in delayed or misdiagnosis with subsequent inappropriate management. Optimal therapy is a challenge for oncologists and ophthalmologists.
authors.affiliation: a Massachusetts Eye Research and Surgery Institution (MERSI) , Waltham , Massachusetts , USA.|b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.
authors.forename: Khawla
authors.initials: K
authors.lastname: Abu Samra
authors.affiliation: a Massachusetts Eye Research and Surgery Institution (MERSI) , Waltham , Massachusetts , USA.|b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.|c Istanbul University, Istanbul Faculty of Medicine , Department of Ophthalmology , Istanbul , Turkey.
authors.forename: Merih
authors.initials: M
authors.lastname: Oray
authors.affiliation: a Massachusetts Eye Research and Surgery Institution (MERSI) , Waltham , Massachusetts , USA.|b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.
authors.forename: Nazanin
authors.initials: N
authors.lastname: Ebrahimiadib
authors.affiliation: a Massachusetts Eye Research and Surgery Institution (MERSI) , Waltham , Massachusetts , USA.|b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.
authors.forename: Stacey
authors.initials: S
authors.lastname: Lee
authors.affiliation: a Massachusetts Eye Research and Surgery Institution (MERSI) , Waltham , Massachusetts , USA.|b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: Anesi
authors.affiliation: a Massachusetts Eye Research and Surgery Institution (MERSI) , Waltham , Massachusetts , USA.|b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA.|d Harvard Medical School , Boston , Massachusetts , USA.
authors.forename: C Stephen
authors.initials: CS
authors.lastname: Foster
mesh_terms: D000328:Adult; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001706:Biopsy; D003131:Combined Modality Therapy; D005134:Eye Neoplasms / Q000175:diagnosis* / Q000628:therapy; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D064090:Intraocular Lymphoma / Q000175:diagnosis* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy; D012189:Retrospective Studies; D016896:Treatment Outcome; D014821:Vitrectomy; D014822:Vitreous Body / Q000473:pathology*
chemical_list: D005938:Glucocorticoids
keywords: Clinical manifestations; intraocular lymphoma; masquerade syndrome; treatment outcomes; uveitis